Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01760928 |
Recruitment Status
:
Completed
First Posted
: January 4, 2013
Last Update Posted
: January 4, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Asthma |
Preparation phase:
Eighteen asthma patients were selected based on physical and medical characteristics. During the year of preparation, several time points of evaluation were planned: evaluation at baseline, maximal exercise test in hypoxia (FiO2: 11%), 24hour stay at cold air environment.
At baseline, medical history was evaluated and clinical examination, ECG, lung function, Fraction of exhaled NO measurement and histamine provocation were performed.
During a second visit, patients stayed for approximately one hour in a chamber to simulate high altitude (FiO2:11%) and performed a maximal exercise test after 30 minutes of rest. Oxygen saturation, ECG and oxygen consumption were continuously monitored. Lung function and fraction of exhaled NO were assessed before and after the test. Also, peripheral blood was drawn before and after the test. This test allowed us to identify whether patients may develop acute mountain sickness later on during expedition.
During a third visit, patients stayed for 24 hours in a indoor ski centre to practice climbing techniques, building up a tent and working with the specialized materials. Temperature at the ski piste varies between -5°C and -10°C. Lung function, fraction of exhaled NO and induced sputum was assessed before and after the stay at the ski centre.
During the expedition, clinical status, heart rate and oxygen saturation were measured daily. Also, lung function and fraction of exhaled NO were regularly measured. A screening for acute mountain sickness was performed daily. Asthmatics patients were supported by two pulmonologist. Before and after expedition, spirometry, histamine provocation and induced sputum were performed.
Study Type : | Observational |
Actual Enrollment : | 18 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | January 2010 |
Actual Study Completion Date : | September 2012 |

Group/Cohort |
---|
Asthma patients
all
|
- To assess the type of airway inflammation evoked by exercise, hypoxia and cold air [ Time Frame: one year ]Sputum cells and cytokine messenger ribonucleic acid will be analyzed to determine the type of airway inflammation that is induced by several triggers (exercise, hypoxia and cold air)
- To predict the occurrence of acute mountain sickness during an expedition to the Aconcagua mountain [ Time Frame: one year ]
- Mean Lake Louise Score in subjects
- Number of subjects with Lake Louise Score > 5
- Mean change in daily asthma symptom score
- Mean change in Asthma control test score
- Number of participants with an acute asthma exacerbation
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- asthma patient
- positive histamine provocation
Exclusion Criteria:
- exacerbation during the year prior to inclusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01760928
Belgium | |
UZ Leuven | |
Leuven, Vlaams-Brabant, Belgium, 3000 |
Study Director: | Sven S Seys, MSc | lab of clinical immunology, O&N I Herestraat 49 - bus 811, 3000 Leuven, België |
Responsible Party: | Dr. Lieven Dupont, Prof. dr., Universitaire Ziekenhuizen Leuven |
ClinicalTrials.gov Identifier: | NCT01760928 History of Changes |
Other Study ID Numbers: |
ML9478 |
First Posted: | January 4, 2013 Key Record Dates |
Last Update Posted: | January 4, 2013 |
Last Verified: | January 2013 |
Additional relevant MeSH terms:
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |